本次获奖是对公司技术创新和研发能力的充分肯定，后续公司将会继续加大科研工作力度，持续提升公 司的技术创新能力，进一步增强公司的核心竞争力。 智通财经APP讯，爱威科技(688067.SH)发布公告，公司近日收到湖北省人民政府颁发的科学技术奖励 证书，公司参与完成的"急性白血病骨髓分子诊断关键技术创新及临床应用"项目荣获2025年度湖北省科 学技术进步奖二等奖。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 ■ 上述医疗器械注册证的取得，有利于丰富公司的产品种类，满足市场需求，增强公司的核心竞争能力。 但上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后的实销售情况取决于未来 市场的推广效果，公司目前尚无法预测上述产品对公司未来营业收入的具体影响。敬请投资者理性投 资，注意投资风险。 爱威科技股份有限公司（以下简称"爱威科技"、"公司"）及其子公司湖南爱威医疗科技有限公司（以下 简称"湖南爱威"）自2025年10月1日起至2025年12月31日 取得境内专利证书11项，其中发明专利5项、 实用新型专利1项、外观设计专利5项；取得境外专利1项；取得医疗器械注册证1项。具体情况如下： 一、专利证书 （1）境内专利 ■ （2）境外专利 ■ 上述专利的取得是公司重要核心技术的体现和延伸，有利于进一步完善公司知识产权保护体系， 发挥 自主知识产权的技术优势，促进技术创新，从而提升公司核心竞争力。 二、医疗器械注册证 特此公告。 爱威科技股份有限公司董事会 2026年1月1日 ...

Core Points - The company, Aiwei Technology Co., Ltd., has obtained 11 domestic patent certificates and 1 foreign patent certificate from October 1, 2025, to December 31, 2025, including 5 invention patents, 1 utility model patent, and 5 design patents [1][2] - The acquisition of these patents reflects the company's core technology and enhances its intellectual property protection system, promoting technological innovation and improving core competitiveness [1] - The company has also obtained a medical device registration certificate, which will enrich its product variety and meet market demand, thereby enhancing its core competitiveness [2] Patent Certificates - The company acquired 11 domestic patents, which include 5 invention patents, 1 utility model patent, and 5 design patents [1] - Additionally, the company secured 1 foreign patent, indicating its commitment to expanding its intellectual property portfolio [1] Medical Device Registration - The medical device registration certificate obtained allows the company to enter the domestic market, although the actual sales performance of the products will depend on future marketing efforts [2] - The company currently cannot predict the specific impact of these products on future revenue [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688067 证券简称：爱威科技 公告编号：2026-001 爱威科技股份有限公司 关于取得专利证书及医疗器械注册证 的自愿性披露公告 上述医疗器械注册证的取得，有利于丰富公司的产品种类，满足市场需求， 增强公司的核心竞争能力。但上述注册证的取得仅代表公司相关产品获得国内市 场准入资格，产品上市后的实销售情况取决于未来市场的推广效果，公司目前尚 无法预测上述产品对公司未来营业收入的具体影响。敬请投资者理性投资，注意 2 爱威科技股份有限公司（以下简称"爱威科技"、"公司"）及其子公司湖 南爱威医疗科技有限公司（以下简称"湖南爱威"）自 2025 年 10 月 1 日起至 2025 年 12 月 31 日 取得境内专利证书 11 项，其中发明专利 5 项、实用新型专 利 1 项、外观设计专利 5 项；取得境外专利 1 项；取得医疗器械注册证 1 项。具 体情况如下： 一、专利证书 | 序号 | 专利名称 | 专利号 | 专利权人 | 申请日期 | 专利 | 取得 | ...

重要内容提示： | 投资标的名称 | 湖南麓影科技有限公司 | | | | --- | --- | --- | --- | | 投资金额（万元） | 1,000 | | | | 投资进展情况 | 完成 | 终止 | 交易要素变更 | | | 1、本次投资完成后，麓影科技成为公司的参股公司。公 | | | | | 司依据签署的相关协议及标的公司章程行使股东权利，麓 | | | | | 影科技的具体经营管理等仍由其现有管理团队负责，本次 | | | | | 投资存在一定的公司治理及管控风险。 | | | | | 2、麓影科技成立时间较短，目前尚未有销售收入及实现 | | | | 特别风险提示 | 盈利。其核心产品高端医学影像 SPECT/CT 尚处于开发之 | | | | | 中，未来能否顺利研发成功及完成产品的医疗器械证书申 | | | | | 报存在一定的不确定性。同时后续麓影科技在实际运营中 | | | | | 还面临宏观经济及行业政策变化、经营管理、技术研发、 | | | | | 市场开发等方面的风险因素，未来经营情况存在一定的不 | | | | | 确定性，本次对外投资存在无法实现预期收益的风险。 ...

Core Insights - The article highlights the rapid growth of the testing and inspection industry in Changsha, with an annual growth rate of nearly 20% and a projected output value of 36.911 billion yuan in 2024, representing over a 50% increase from three years ago [5][12]. Industry Development - Changsha has been recognized for its industrial clusters, with the inspection and testing instrument equipment cluster in Yuelu District being included in the national list of characteristic industrial clusters for small and medium-sized enterprises [9]. - The city has cultivated three national advanced manufacturing clusters and three national characteristic industrial clusters for small and medium-sized enterprises, along with seven provincial advanced manufacturing clusters [9]. Cluster Ecosystem - The inspection and testing industry in Changsha is characterized by a collaborative ecosystem, with major companies like Sanofi Bio and Aiwei Technology leading the way, supported by over 400 technology-based SMEs [10]. - The industry benefits from a strong synergy between research, manufacturing, and service, facilitated by local universities and research institutions [10][12]. Innovation and Technology - Sanofi Bio, as the fourth largest blood glucose meter manufacturer globally, exemplifies the success of the cluster's collaborative model, achieving significant breakthroughs in glucose sensor technology [10]. - The cluster has implemented a "chain leader system" to address industry challenges and enhance cooperation among enterprises [12]. Global Expansion and Digital Transformation - The cluster is focusing on digital transformation and international cooperation, with companies like Sanofi Bio providing services to over 25 million users globally, and achieving over 40% of revenue from overseas markets [16]. - The industry is also embracing green development, with companies obtaining environmental management certifications and reducing operational costs while gaining a competitive edge in international markets [16]. Collaborative Initiatives - The industry alliance organized an innovation development exchange conference to promote global collaboration, sharing successful cases of overseas testing services [17]. - The shift from individual competition to collective development is emphasized, with Changsha's strategy aimed at enhancing its position as a significant manufacturing hub in China [18].

Group 1 - The core transaction on December 3 involved a block trade of 125,000 shares of Aiwei Technology, with a transaction value of 3.005 million yuan, at a price of 24.04 yuan, which represents a discount of 4.49% compared to the closing price of the day [2][3] - Over the past three months, Aiwei Technology has recorded a total of six block trades, amounting to a cumulative transaction value of 18.5795 million yuan [2] - The closing price of Aiwei Technology on the day of the transaction was 25.17 yuan, reflecting a decline of 1.83%, with a turnover rate of 1.58% and a total trading volume of 27.0651 million yuan [2][3] Group 2 - The latest margin financing balance for Aiwei Technology is 40.3061 million yuan, which has decreased by 1.73 million yuan over the past five days, representing a decline of 4.12% [3] - Aiwei Technology was established on March 16, 2000, with a registered capital of 68 million yuan [3]

Group 1 - The core transaction involved Awei Technology, with a total of 125,000 shares traded on December 3, resulting in a transaction amount of 3.005 million yuan, which accounted for 9.99% of the total trading volume for that day [1][2] - The transaction price was 24.04 yuan per share, representing a discount of 4.49% compared to the market closing price of 25.17 yuan [1][2] - The buying brokerage was Guohai Securities Co., Ltd. Shandong Branch, while the selling brokerage was Guolian Minsheng Securities Co., Ltd. Beijing Building Materials [2]

Group 1 - The core transaction on December 2 involved a block trade of 125,000 shares of Aiwei Technology, with a transaction value of 3.0613 million yuan, at a price of 24.49 yuan, representing a discount of 4.49% compared to the closing price of the day [2][3] - Over the past three months, Aiwei Technology has recorded a total of five block trades, amounting to a cumulative transaction value of 15.5745 million yuan [2] - The closing price of Aiwei Technology on the same day was 25.64 yuan, reflecting a decrease of 0.47%, with a daily turnover rate of 2.03% and a total trading volume of 35.1212 million yuan [2] Group 2 - The latest margin financing balance for Aiwei Technology is 39.9355 million yuan, which has decreased by 2.5106 million yuan over the past five days, representing a decline of 5.91% [3] - Aiwei Technology was established on March 16, 2000, with a registered capital of 68 million yuan [3]

Group 1 - The core transaction involved Awei Technology, with a total of 125,000 shares traded, amounting to 3.0613 million yuan, which represented 8.02% of the total trading volume for the day [1] - The transaction price was 24.49 yuan per share, reflecting a discount of 4.49% compared to the market closing price of 25.64 yuan [1] - The buying brokerage was Guohai Securities Co., Ltd. Shandong Branch, while the selling brokerage was Guolian Minsheng Securities Co., Ltd. Beijing Jianfen [2]